< Back to previous page
Researcher
Dirk Hose
- Keywords:Medicine
- Disciplines:Other basic sciences not elsewhere classified
Affiliations
- Translational Oncology Research Center (Research group)
Member
From1 Jan 2023 → Today - Translational Oncology Research Center (Research group)
Member
From1 Jan 2024 → 30 Sep 2025 - FORMER_Hematology (Research group)
Member
From22 Mar 2021 → 1 Jan 2023 - Basic (bio-) Medical Sciences (Department)
Member
From1 Mar 2020 → 30 Sep 2025 - Basic (bio-) Medical Sciences (Department)
Member
From1 Mar 2020 → 20 Oct 2022
Publications
1 - 10 of 111
- Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma(2025)Published in: J Clin OncolISSN: 0732-183XIssue: 11Volume: 43Pages: 1289-1301
- Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma(2024)Published in: J Hematol OncolISSN: 1756-8722Issue: 1Volume: 17
- Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial(2024)Published in: Hematology (Amsterdam, Netherlands)ISSN: 1024-5332Issue: 1Volume: 29
- Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation(2024)Published in: JCO precision oncologyISSN: 2473-4284Volume: 8
- CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients(2024)Published in: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.KISSN: 0887-6924Issue: 7Volume: 38Pages: 1621-1625
- Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries(2024)Published in: Int. J. Mol. Sci.ISSN: 1661-6596Issue: 12Volume: 25
- Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics(2024)Published in: Cancer research communicationsISSN: 2767-9764Issue: 4Volume: 4Pages: 1150-1164
- Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6)(2024)Published in: The Lancet. HaematologyISSN: 2352-3026Issue: 2Volume: 11Pages: e101-e113
- Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody(2024)Published in: Frontiers In ImmunologyISSN: 1664-3224Volume: 15
- Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers(2023)Published in: J Hematol OncolISSN: 1756-8722Issue: 1Volume: 16